Clinical Trial Update: Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers [Phase 1]

View source ↗

Summary

This entry covers a Phase 1 safety study of a human MUC-1 adenoviral vector vaccine designed for immunotherapy of epithelial cancers. The study targets several …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer

Drugs mentioned

• MUC-1 adenoviral vector vaccine (MUC-1 vaccine)

Snippet

Sponsor: Singapore Clinical Research Institute | Conditions: Epithelial Cancers of the Lung, Breast, Ovary, Prostate and Colon | Phase 1 | Status: UNKNOWN